home Search results for 'CAR-T'
Medical

Car-T Therapy Ide-Cel For Multiple Myeloma Prolongs Patient Survival By 2-Fold!

For patients with relapsed and refractory multiple myeloma, the CAR-T cell therapy Ide-cel resulted in a two-fold increase in the average length of time that patients' tumours did not progress compared to standard treatment, with 71% of patients experiencing substantial tumour regression and 39% experiencing complete tumour disappearance.

Apparatus

Car-T From Carvykti, a Good Run Or a Bubble Fest

Carvykti gains new ground and competes with its "predecessor"!

Medical

Two In a Row From Science: Car-T Cells Are Back With a New Upgrade That May Eradicate Deadly Solid Tumours!

Science has published two consecutive research articles that suggest new ways to improve the efficacy of CAR-T for solid tumours.

Apparatus

New CAR-T Therapy CB-010, Granted Two FDA Designations And Three Patients Are Cancer-Free For Six Months!

According to an announcement from Caribou Biosciences, the FDA has granted advanced therapy designation in regenerative medicine for the cutting-edge CAR-T therapy CB-010 for the treatment of relapsed or refractory large B-cell lymphoma and fast track designation for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.

Medical

Cutting-edge Medicine: Getting Immune Cells To Kill Immune Cells Can Actually Shrink Solid Tumours!

CAR-T therapy is a cellular immunotherapy treatment that has become very popular in recent years. This therapy uses genetic engineering techniques to upgrade the patient's immune T cells in vitro, before entering the body to exert a powerful anti-cancer effect. Currently, CAR-T therapy has performed very well in blood cancers such as lymphoma and leukaemia.